Candel Therapeutics, Inc. (Nasdaq: CADL) reported its financial results for the third quarter ended September 30, 2026, and announced a specific timeline for its regulatory submission strategy. The company stated that it is currently in ongoing dialogue with the U.S. Food and Drug Administration (FDA) regarding the submission of a Biologics License Application (BLA) for its candidate aglatimagene besadenovec (aglatimagene) in prostate cancer. Due to timelines associated with certain assay refinement, the company plans to submit this BLA in the middle of 2027 pending the outcome of this dialogue.
In terms of financial position, Candel reported cash and cash equivalents of $203.1 million as of September 30, 2026. The company stated that this cash balance is expected to be sufficient to fund its current operating plan into the second quarter of 2028.
The company also highlighted recent corporate and clinical developments. At the Society for Immunotherapy of Cancer’s 41st Annual Meeting, Candel presented three posters featuring data on aglatimagene and linoserpaturev. Key findings included evidence of systemic activation of CD8 positive T cells following aglatimagene treatment, as well as updated overall survival data from a phase 1b trial of linoserpaturev in recurrent high-grade glioma.
On the corporate leadership front, Candel appointed Martine Zimmermann, PharmD, to its Board of Directors in September 2026, and Maria Ostrovsky, JD, as General Counsel in October 2026.
